$119 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 51 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 250.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
FOLD | Buy | AMICUS THERAPEUTICS | $21,374,000 | +57.3% | 1,964,565 | +20.3% | 18.00% | +96.1% |
LBIO | New | LION BIOTECHNOLOGIES | $8,104,000 | – | 669,196 | +100.0% | 6.83% | – |
CEMP | New | CEMPRA | $5,846,000 | – | 170,400 | +100.0% | 4.92% | – |
ASND | New | ASCENDIS PHARMA A Sspons adr | $3,966,000 | – | 228,612 | +100.0% | 3.34% | – |
LMAT | Buy | LEMAITRE VASCULAR | $3,907,000 | +10.3% | 466,279 | +0.7% | 3.29% | +37.5% |
OXFD | New | OXFORD IMMUNOTEC GLOBAL PLC | $3,129,000 | – | 222,226 | +100.0% | 2.64% | – |
INSM | Buy | INSMED | $3,120,000 | +1436.9% | 150,000 | +1040.3% | 2.63% | +1818.2% |
RRM | Buy | RR MEDIA LTD | $3,106,000 | +7.5% | 405,424 | +1.0% | 2.62% | +33.9% |
BBW | Buy | BUILD A BEAR WORKSHOP | $2,948,000 | +65.2% | 150,000 | +69.0% | 2.48% | +105.9% |
CASM | Buy | CAS MED SYS | $2,884,000 | +234.6% | 2,160,000 | +313.4% | 2.43% | +316.6% |
IRIX | Buy | IRIDEX | $2,515,000 | +40.0% | 235,517 | +12.7% | 2.12% | +74.5% |
PODD | New | INSULET | $2,077,000 | – | 62,265 | +100.0% | 1.75% | – |
SPY | New | SPDR S&P 500 ETF TRput | $2,064,000 | – | 10,000 | +100.0% | 1.74% | – |
AUPH | New | AURINIA PHARMACEUTICALS | $1,875,000 | – | 430,000 | +100.0% | 1.58% | – |
FLKS | New | FLEX PHARMA | $1,764,000 | – | 90,000 | +100.0% | 1.49% | – |
CBMX | Buy | COMBIMATRIX CORPORATION | $1,672,000 | +51.9% | 880,244 | +3.2% | 1.41% | +89.2% |
AVID | New | AVID TECHNOLOGY | $1,502,000 | – | 100,818 | +100.0% | 1.26% | – |
New | NEURODERM LTD | $1,385,000 | – | 103,167 | +100.0% | 1.17% | – | |
INNL | Buy | INNOCOLL AGspons adr | $1,307,000 | +34.2% | 164,459 | +0.2% | 1.10% | +67.3% |
CRDC | Buy | CARDICA | $1,146,000 | +11.7% | 1,819,436 | +24.1% | 0.96% | +39.2% |
EGOV | New | NIC | $1,010,000 | – | 57,143 | +100.0% | 0.85% | – |
NXTM | New | NXSTAGE MEDICAL | $928,000 | – | 53,665 | +100.0% | 0.78% | – |
SRNE | New | SORRENTO THERAPEUTICScall | $925,000 | – | 80,000 | +100.0% | 0.78% | – |
AVEO | New | AVEO PHARMACEUTICALS | $861,000 | – | 593,872 | +100.0% | 0.72% | – |
EXEL | New | EXELIXIS INCcall | $846,000 | – | 329,000 | +100.0% | 0.71% | – |
DYAX | New | DYAX CORPcall | $838,000 | – | 50,000 | +100.0% | 0.71% | – |
AGRX | New | AGILE THERAPEUTICS | $750,000 | – | 80,959 | +100.0% | 0.63% | – |
OTIC | New | OTONOMY | $707,000 | – | 20,000 | +100.0% | 0.60% | – |
DSCO | New | DISCOVERY LABORATORIES | $468,000 | – | 393,148 | +100.0% | 0.39% | – |
SAGE | New | SAGE THERAPEUTICS | $402,000 | – | 8,000 | +100.0% | 0.34% | – |
SMLR | New | SEMLER SCIENTIFIC | $403,000 | – | 115,148 | +100.0% | 0.34% | – |
MRNS | New | MARINUS PHARMACEUTICALS | $325,000 | – | 36,107 | +100.0% | 0.27% | – |
ZSAN | New | ZOSANO PHARMA | $222,000 | – | 21,956 | +100.0% | 0.19% | – |
ANGO | New | ANGIODYNAMICS | $178,000 | – | 10,000 | +100.0% | 0.15% | – |
TXMD | New | THERAPEUTICSMD | $114,000 | – | 18,915 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
IRIDEX CORP | 20 | Q3 2019 | 8.1% |
ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
VERACYTE INC | 19 | Q3 2019 | 10.1% |
ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.